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Abstract
Background:  In both USA and Europe operate companies selling Direct-to-consumer 
genetic tests (DTC).  These tests are offered to healthy people aiming to identify 
predispositions to complex diseases and to take  preventive measures.  Several DTC-
nutrigenetic  tests  (DNTs)  are available on the market.  They  propose  the definition of a 
personalized diet,  on the basis of the investigated genetic variants, which  would reduce the 
risk of developing those diseases which have been  associated to specific genetic markers. 
However, the risk/benefit balance of  exposing unselected population to genetic testing 
without any medical surveillance is far from be established. Furthermore, it lacks an accepted 
procedure to select which genetic markers needs to be investigated, to evaluate their specific 
role and,  as consequence,  to define a personalized diet.  Within this context, the European 
Society of Human Genetics (ESHG) released a statement regarding the DTC tests that has 
been ratified by several national societies including the Italian one. 
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In the present study we analyzed the DNT offered in Italy,  the state of the art and the 
abidance with the ESHG statement. 
Methods: We queried web  search engine for the DNT offered to italian population, 
portraying a non-specialized customer.  We examined the DNTs vendor websites and/or 
directly contacted the companies to collect information on: 1)  genetic marker essayed,  2) 
diseases and phenotypes considered and 3)  kind of  dietary advices provided.  Finally,  we 
evaluated the abidance to the ESHG statement. The study was conducted between November, 
2010 and May, 2011.
Results:  Six companies operate in Italy with a total of seven different DNTs offered.  Both 
studied phenotypes and investigated genetic markers were very different among companies, 
with  a  relative  higher  level  of  agreement  for  phenotype  than  for  genes.  None of the 
companies described the methods used to select markers and to define diet advices. None of 
the companies showed a complete agreement to the statement of the ESHG. 
Conclusion: Although DNT companies' efforts are worthy, a standardization of methods and 
a more strictly agreement with ESHG statement should be encouraged.
Abbreviations:  DTC, direct-to-consumer genetic test; DNT, DTC nutrigenetic test; ESHG, 
European Society of Human Genetics.
Introduction
The  identification  of  the genetic basis of several common multifactorial disease and the 
perspective of the application toward a personalized medicine led, in the recent years, to the 
development of an increasing number of predictive genetic tests. In addition, the continuous 
biotechnological advancement is reducing the costs of genetic testing and is creating potential 
business opportunities.  Indeed,  in North America and in Europe,  several companies have 
been established to sell “direct-to-consumer” genetic tests (DTC). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.7
13
5.
1 
: P
os
te
d 
3 
Ap
r 2
01
2
These tests are offered to unselected customers, usually through websites or pharmacies, and 
without a specific medical counselling. In the typical procedure, the customer purchases the 
test online,  receives a kit to collect exfoliated oral cells and sends the sample  back to the 
company.  Company extracts DNA,  characterizes a set of genetic markers and email  the 
results with variable ancillary information, such as results interpretation and/or personalized 
advices. 
Undoubtedly,  DTC have potentially important advantages.  Customers can have an easy 
access to genetic testing [1],  acquire consciousness of their disease risk and receive 
personalized suggestions to modify the lifestyle [2, 3]. However, these tests are proposed to 
healthy people without the mediation of any healthcare professional whereas all the persons 
undergoing a genetic test should receive a pre- and a post-test genetic counselling explaining 
scope,  limitations  and  uncertainty  of  the  results  obtained.  Moreover,  the  genetic-tests 
interpretation have the peculiarity to be perceived as definitive and unmodifiable, therefore, 
even  when  negative,  a  clear  explanation  of  the  real  prediction  ability  of  test  should  be 
provided.  All  these  concerns  are  amplified  in  the  case  of  complex  disease  where the 
prediction ability of these tests is largely unproven  [4, 5, 6, 7].  The genetic basis of most 
complex diseases are, in fact, still in active state of definition only partially understood and 
the methods to calculate the risk for a single individual are not defined [8, 9]. Anecdotal cases 
suggest that different companies assessed different risk to the same individual for the same 
phenotype [10].
Among others, nutrigenetic DTCs are becoming very popular. Many companies are, in fact, 
selling DTC nutrigenetic tests claiming to identify individuals with genetic risk to develop 
diseases, such as type 2 diabetes and osteoporosis, and provide them with tailored nutritional 
advices or a personalized diets [11].  Unfortunately, only in few cases an agreement among 
researchers on which diet suggest to individuals with specific genetic background has been 
reached. 
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For these reasons, the selling of DTC tests in Europe is rising several  concerns  among the 
scientific  societies  and  the  regulating  bodies.  The  European  Society  of  Human  Genetics 
(ESHG) released a statement on DTC genetic testing for health related purposes that has been 
approved  by  the  Società  Italiana  di  Genetica  Umana  (SIGU)  [12,  13].  This  statement 
highlights  several relevant issues: the need of a medical counsellings before and after each 
test, the transparency in the communications process, the legal age for testing; the acceptance 
of an informed consent, the respect for the customers’ privacy. 
In the present study we analyzed DNTs  available in Italy,  their state of the art and their 
abidance with the ESHG statement. 
Data and methods
Three independent researchers queried a web  search engine for DTNs offered to Italian 
population.  The searched keyword was:  “nutrigenetics”  on Google Italia 
(http://www.google.it/) and the first 100 results were screened.  The results included private 
practices and companies, we only selected those companies offering genetic tests directly to 
customers without a genetic counselling.
We examined,  as we were the customer,  the companies’ websites and/or directly contacted 
them to collect  further data.  We collected information on:  investigated clinical  phenotypes, 
genes and SNPs assayed,  methods and algorithms used for the risk prediction,  costs of the 
services, conflict of interests (i.e.  nutritional supplements selling), legal and ethical aspects. 
We also assessed if companies provided scientific references supporting their test, how those 
references were obtained and how they defined the predictive value for each investigated 
SNP. 
We considered as “output” of the DNTs the answer that the customer automatically receives 
after testing and not any other additional information that he/she could potentially obtain by 
contacting help desks or other customer services. 
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We also checked if  other  supplementary  services were offered  to  customers  by the 
companies, i.e. if the companies offered the chance to meet or to talk to a specialist (medical 
doctor, genetic counselor,  dietitian) or if a tailored help desk service was provided (with 
professional or non-professional employees).  Finally, we searched for laboratory quality 
certifications on companies websites.
All the data were collected from November, 2010 to May, 2011.
To  assess  the  overlap  in  terms  of  common  clinical  phenotypes  and  genes  analyzed  by 
different companies, we used the Jaccard index (J) [14]. According to this test, two sets of 
items are as more similar as the J is higher. J is defined as the ratio between the items that are 
common to the two sets (intersection) on all the items that belong to one of the sets (union). 
Defining A and B as the items of the first and second set, respectively, the J can be defined 
as:
J (A, B) = |A ∩ B| / |A U B |
To compute genes overlap between companies, we searched for unequivocal IDs in the NCBI 
Entrez Gene database.  We did  not obtain exhaustive SNP data,  because the  information 
provided by the  companies  were,  usually,  incomplete.  We manually grouped the clinical 
phenotypes declared by companies in few categories.
To evaluate if companies met ESHG statements’ criteria [12], we collected information in a 
structured way. Firstly, we designed an evaluation list (Table 1), in which each point refers to 
an  aspect  of  the  ESHG statement,  then  we  collected  data  and  compared  them with  the 
statements.
RESULTS AND DISCUSSION
DNT services
We found six DTC Italian companies offering seven different DNT (Table 2). One company, 
G&Life, offering two DNTs, namely: G-Diet Lifeplan and G-Profile Nutrigenetics.
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All  DNTs  were  presented  in  websites  with  different  extent  of  documentation  and 
explanations. Regarding the sample collection, six DNTs send sample collection kits at home 
(G-Diet Lifeplan, G-Profile Nutrigenetics, Genoma DNT, Nutrisalus.Gen, Test Nutrigene and 
Kriagen DNT),  four  collect  samples  by inviting  customers  in  their  laboratories  (Genoma 
DNT,  Nutrisalus.Gen,  Test Nutrigene and Kriagen DNT), one through affiliated pharmacies 
(Vitalybra),  and  three  through  health  professional  practices  (G-Diet Lifeplan,  G-Profile 
Nutrigenetics, and Vitalybra). All DNTs collected sample by means of a buccal swab.
Table  3  reports  the  main  characteristics  of  the  considered  DNTs.  We  revealed  a  cost 
difference among the companies that can be accounted to the different number of genetic 
markers analyzed and to the differences in services offered.
Analyzed genes, SNPs and phenotypes
Companies communicated at some extent the genes analyzed for each DNT (Table 3 and 
Table 4). However, only for four DNTs the complete list was provided, while for the three 
others the information were incomplete. For instance,  Nutrisalus.Gen listed 19 single genes 
and a group of non-specified interleukin genes, while Test Nutrigene and Kriagen DNT did 
not specified which genes were assayed for celiac disease. The information regarding the 
SNPs  were  more  incomplete  (Table  3  and  Table  4).  Only  Vitalybra provided  accurate 
information about tested SNPs (including the dbSNP  reference SNP code) and the at-risk 
genotype  for  each phenotype.  Test Nutrigene,  Kriagen DNT and  Genoma DNT provided 
enough information to identify SNPs in databases, while Nutrisalus.Gen, G-diet Lifeplan, G-
profile Nutrigenetics did not provide information about SNP (Table 4). Although this lack of 
information, when possible we tried to extract the gene and SNP lists for DNTs (Table 4 -  
S2). 
We looked for genes assayed by more DNTs (Figure 1) and found that no gene was analyzed 
by all the DNTs. This would suggest that scientists and companies have still not reached an 
agreement on a core set of relevant genes with a nutrigenetics impact. On the contrary more 
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than a third of genes (22 out of 60, 37%) were tested by a single DNT. Despite this little 
overlap, it is remarkable that the two most studied genes, LCT and MTHFR (tested by six 
DNTs),  are  among  the  few ones  that  have  polymorphisms  with  a  proven  importance  in 
nutrigenetics. 
The assayed SNPs covered a wide spectrum of functional roles. Some polymorphisms were 
predisposing factors for multifactorial  diseases, usually associated with a mild increase of 
disease risk. Others, such as those regarding celiac disease were susceptibility factors with a 
high negative predictive value [15, 16]. Finally, few ones were mendelian disease-causing 
mutations, as the  ALDOB gene mutation for the familiar fructose intolerance [17] and the 
APOB gene (R3500Q mutation) for the familial defective apolipoprotein B-100 [18]
To assess how companies selected genes and SNPs we evaluated if DNT companies reported 
reference  studies  and  described  methods  used  to  select  them (Table  3).  Even  if  with  a 
different level of accessibility, only  Genoma DNT and  Test Nutrigene, clearly reported the 
scientific studies used for the selection. No company declared how reference studies were 
selected.  Nevertheless,  authors  believe  that  defining  a-priori  criteria  to  select  reference 
studies would help to proceed to a non-arbitrary selection of markers avoiding selection bias. 
The  ESHG  statement  invites  companies  to  provide  accurate  and  accessible  labelling 
information about genetic tests. By this point of view, the incomplete disclosure of data and 
procedure used by companies seems not to meet that statement. 
We evaluated the clinical phenotypes considered by DNTs and checked whether there was an 
overlap among DNTs. It resulted that phenotypes analyzed were widely different and the 
most analyzed pertains to moderate hyperhomocysteinemia, primary lactose intolerance and 
dyslipedemia. (Table 6). The clinical phenotypes are in many cases diseases preventable by a 
modification of lifestyle. In this light, it seems that DNTs would meet customers wishes as 
detected by an UK survey [19]. In that study most of the potential customers declared that 
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they would perform a DTC genetic test to reduce their risk to develop diseases by modifying 
their lifestyle.
Regarding the nutrigenetics, a clinical phenotype of relevance is the obesity. Although there 
are no direct evidences that individuals undergoing a DNT wants to lose weight and few 
scientific  evidences  supporting  the  utility  of  a  genotype-specific  dietary  plans  in  losing 
weight  [20, 21], appear presumable that weight control could be one of the major drive for 
individuals undergoing these kind of tests. Nevertheless, only a few of DNT consider obesity 
(8%).
Finally, the Jaccard analysis showed which DNTs are more similar for assayed genes and 
clinical  phenotypes  (Table  5).  We  detected  that  overlap  both  in  terms  of  genes  and 
phenotypes  was  generally  low,  however,  in  all  cases  the  jaccard  index  was  higher  for 
phenotypes than for genes. This could suggest that a relative higher level of agreement has 
been reached for relevant phenotype in nutrigenetics than for genes. 
Nutritional recommendations 
Outputs of DNTs resulted to range from a complete dietary plan to the sole list of assayed 
SNPs  (Table  3).  G-diet Lifeplan,  G-profile Nutrigenetics and  Vitalybra elaborated  an 
independent  semi-quantitative  risks  for  some  diseases  on  the  basis  of  the  genetic  test. 
Genoma DNT and G-diet Lifeplan returned a personalized dietary plan, while Test Nutrigene, 
Vitalybra, G-diet Lifeplan and Nutrisalus.Gen provided nutritional advices on the basis of the 
carried variants for specific phenotypes. Kriagen DNT and Genoma DNT only reported a list 
with  the  results  of  the  genotyping without  any advice.  They  offered  as  basic  option  the 
genetic  test  without  an  interpretation,  nevertheless,  Genoma DNT offers,  as  additional 
service,  a help desk with molecular  geneticists  and/or a nutritional  consult  in Rome (this 
latter  with  fee)  and  Kriagen DNT offers  an  help  desk  with  molecular  geneticists  and 
dietitians. 
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Regarding how the nutritional advices were formulated, all the DNTs used genetic data plus, 
in some cases, other information. For instance, to formulate a complete dietary plan  G-diet 
Lifeplan uses genetic data, a lifestyle questionnaire, and a PTC (phenylthiocarbamide) paper 
test.  G-profile Nutrigenetics uses only genetic data and the PTC paper test.  Vitalybra,  Test 
Nutrigene’  and  Nutrisalus.Gen’s  results  rely  on  the  sole  genetic  data.  Nevertheless, 
companies did not describe methods used to predict disease risk and to define the advices. 
Agreement to the ESHG statements
In this section we focused on the ethical and legal issues of about DNTs raised by ESGH 
statements.  We formulated  an evaluation  list  (Table  1)  to compare  the companies  policy 
agreement to the ESHG statement. According to results of our list, none of the companies 
showed a full agreement with the ESHG statement (Table 7).  We would underline that we 
did not purchase any DNT. We based our analysis only on information present on websites 
and  collected  by  direct  contacts  with  companies  and  resellers.  Part  of  the  information 
considered in this section, especially regarding privacy and biological sample destiny, could 
be  potentially  reported  in  other  documentation,  i.e.  informed consent  and contracts,  only 
accessible to customers and therefore unavailable to us. 
ESHG  statement  indicates  pre-test  and  post-test  genetic  counselling  as  mandatory  and 
indicates as preferable that they are performed by counselors external to the company. Of the 
considered DNTs only five offered an help desk with the possibility to talk with a genetic 
counselor,  a  physician,  or  a  dietitian.  We believe  that  providing an help desk cannot  be 
considered  equivalent  to  a  genetic  counselling,  however,  this  failure  probably  should  be 
accounted more to the nature of DNTs (direct to consumer) than to the single companies 
strategies. Probably, the main issue raised by this type of services is the exposition of large 
part  of  asymptomatic  population  to  genetic  tests  without  the  intermediation  of  a  health 
professional.  The  opportunity  for  people  to  access  to  valuable  information  for  lifestyle 
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modification faces the risk that  an individual  can overestimate  a test  result  indicating  an 
increased risk or, on the contrary, feeling too reassured by one with a reduced risk. 
Another important concern was the potential conflict of interest of companies offering DNTs. 
None of  them clearly  stated  that  no  conflict  of  interest  exists.  However,  when company 
websites were carefully analyzed, we revealed that a potential conflict of interest may occur 
for at least two companies (also selling nutritional supplements). In fact, they sold DNTs and 
advice nutritional supplements, in one case also on the basis of the genetic test results. 
Regarding personal information privacy and biological sample destiny we revealed different 
level of disclosure among companies.  Five of them assured that personal information are 
treated  in  a  confidential  manner  and  that  biological  sample  will  be  destroyed  after  the 
analysis. For the remaining two companies we could not obtain information on this regard. In 
details, G-diet Lifeplan, G-profile Nutrigenetics declared that biological and personal data of 
the  customer  are  treated  in  confidential  manner  and that  are  not  communicated  to  other 
subjects. The biological samples are treated in an anonymous way, lab operators do not know 
the identity of the customer, and samples are destroyed at the end of the analysis.  Genoma 
DNT and Kriagen DNT declared that biological and customer personal data are treated in 
confidential manner and samples are destroyed at the end of the analysis. When contacted 
Nutrisalus.Gen operators  declared  that  access  to  personal  information  is  restricted  to 
authorized operators and that details on personal information privacy and sample destiny are 
reported in the informed consent. We could not obtain on  Vitalybra website or contacting 
Vitalybra pharmacies  any  detail  regarding  personal  information  privacy  and  biological 
sample  destiny.  When  contacted,  Test Nutrigene operators  did  not  disclose  any  clear 
information  on procedure  regarding  personal  information  privacy  and  biological  samples 
destiny,  declaring  that  DNA  extraction  and  genotyping  were  performed  by  an  external 
laboratory.
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All  the DNTs, were available  for minors.  This  point  is  in  clear  contrast  with the ESHG 
statement  on  direct-to-consumer  genetic  tests  [12]  and  with  ESHG recommendations  on 
genetic  testing  on  asymptomatic  minor  [22].  According  to  published  recommendations, 
testing on a minor should be performed only for diseases substantially influenced by genetic 
variations, for which a medical procedure is needed to prevent or reduce the burden of the 
disease and for which a delay until the legal age should be avoided. DNTs does not belong to 
the this type of genetic testing, therefore, testing on minors should be avoided. 
One of limitation of the study is the possible skipping of DNTs services operating in Italy. 
However, we used a procedure similar to that of a customer that is looking for DNTs on 
internet,  the  web  search  was  repeated  by  three  operators  and  the  first  100  results  were 
analyzed, probably more than those usually considered by a typical internet user. A further 
limitation would be that we did not purchased any DNT, therefore we did not experience the 
testing procedure, nor we consulted contracts, informed consents and answers. However, we 
were particularly interested to the pre-test phase, in order to known information provided to 
customers before they decide to perform a DNT.
CONCLUSION
Direct to consumers-nutrigenetic tests (DNTs) represent an important evolution toward the 
personalized medicine and it are expected to increase their relevance in the near future. Our 
study revealed that DNTs are common in Italy even if information provided by the companies 
are at variable extent of completeness, particularly about the genetic markers assayed and the 
methods used for risk calculation. Furthermore, the companies seems to agree only partially 
with the ESHG statements and recommendations.
DNT is one one of the instruments toward the practical application of personalized medicine, 
therefore, initial efforts made by companies should be considered of great interest. However, 
a  more  strict  collaboration  among  scientists,  regulatory  bodies  and  private  companies  is 
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needed to define an agreement on scientific, ethical and legal aspects of direct-to-consumer 
nutrigenetic testing. 
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TABLES
Table 1 Evaluation list
Quality lab certifications
Personal counseling provided
Statements about conflict of interests
Destiny of DNA samples
Information about who has access to personal data
Test on a minor
Table 2  DNTs companies
Company Location Website
Laboratorio Genoma Roma www.laboratoriogenoma.eu
Kriagen-Krian Quartu www.kriagen.it
Laboratorio De Sanctis Roma www.nutrigene.it
Planet Milano www.vitalybra.com
G&Life Trieste www.glifeprogram.com
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Table 3 DNTs service characteristics
Company G&Life De Sanctis Genoma Planet Kriagen Oxi.Gen 
DNT G-profile Nutrigenetics G-diet Lifeplan Test Nutrigene
Genoma
DNT Vitalybra 
Kriagen
DNT Nutrisalus.Gen
Costs (€) 384 744 200 840 230 320 600
Number of genes 20 20 14+UNK* 37 7 2* 19+UNK**
Number of SNPs UNK UNK 14 53 9 UNK UNK
Studies for SNPs 
selection NO NO YES YES NO NO NO
SNPs selection 
criteria UNK UNK UNK UNK UNK UNK UNK
Personalized 
nutritional 
advices/plans
ADVICES PLAN ADVICES NO*** ADVICES NO**** ADVICES
Personalized 
nutritional 
advices/plans 
methods
UNK UNK UNK UNK UNK UNK UNK
*It was not specified the genes tested for celiac disease
** It was not specified the genes tested for interleukin panel and a further gene was untraceable
*** The dietary plan is provided only to customers that go to dietary practitioner paying an additional cost
**** The nutritional advices is provided only upon request
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Table 4  Analyzed SNPs for tested genes
Genes G&Life DNTs* Genoma DNT Test Nutrigene Nutrisalus.Gen Kriagen DNT Vitalybra
ACE ? 1 ?
ACT 1
ADH1C 1
ADRA2B 1
ADRB1 1
ADRB2 2
ADRB3 1
ALDOB ? 1
APOA1 1 1
APOA5 ?
APOB 1 ?
APOC3 2 1
APOE 2 ?
CAT ?
CBS 2
CETP 2 ?
CHRNA3 ?
COL1A1 1 ?
CTR 1 ?
CYP1A2 3 1 1
ENOS ?
ESR1 ? 2 ?
FTO ? 1
GCKR ?
GHRL ?
GJA4 1
GSTM1 1 ?
GSTP1 2 ?
GSTT1 1 ?
HMGCR 1
IL10 1
IL1B 1
IL6 2 1
LCT ? 1 1 ? 1
LDLR ?
LEP ?
LEPR ?
LPL ? 1 1
LRP5 ?
MC4R ?
MMP3 1
MnSOD 2 1 ?
MTHFR ? 2 1 2 1
MTR 1 ?
MTRR 1 ?
NAT2 2
NOS3 2
NPY 1
PGC1A ?
PON1 1
PPARA 1
PPARG ? 1 1
RETN ?
SLC6A4 1
SOD3 1
SREBF2 1
TAS2R38 ?
TCF7L2 ?
TNFα 1 1
VDR 3 1 ? 2
* For both G&Life DNTs, G-diet Lifeplan and G-profile Nutrigenetics, are tested the same genes
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Table 5 DNTs companies phenotypes (J1) and genes (J2) Jaccard Index
  
    Nutrisalus.Gen     Vitalybra     Genoma DNT    Test Nutrigene    Kriagen DNT
J1 J2 J1 J2 J1 J2 J1 J2 J1 J2
G&life DNTs 0.230 0.102 0.272 0.074 0.285 0.087 0.222 0.117 0.111 0.045
Nutrisalus.Gen 0.25 0.07 0.333 0.25 0.315 0.151 0.2 0.09
Vitalybra 0.307 0.09 0.235 0.142 0 0
Genoma DNT 0.35 0.196 0.090 0.025
Test Nutrigene 0.133 0.062
Table 6 DNTs Phenotypes
Primary lactose intolerance 12%
Moderate hyperhomocysteinemia 11%
Dyslypedemia 11%
Detoxification 10%
Osteoporosis 8%
Obesity and type 2 diabetes 8%
Inflammatory response 6%
Hypertension 4%
Bitter/sweet taste 4%
Nicotine dependence 4%
Anaerobic Physical Activities 4%
Celiac disease 4%
Appetite levels 4%
Hereditary fructose intolerance 4%
Others 6.00%
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.7
13
5.
1 
: P
os
te
d 
3 
Ap
r 2
01
2
Table 7 Agreement to ESHG statement
G&Life DNTs
Test 
Nutrigene
Genoma 
DNT
Vitalybra
Kriagen
DNT
Nutrisalus.Gen
Quality laboratory certifications NO NO YES NO NO YES
Personal consult provided YES NO YES NO YES YES
Statements about conflict of interests NO NO NO NO NO NO
Destiny of DNA samples YES NO YES NO YES NO
Information about who has access to 
personal data
YES NO YES NO YES YES
Avoiding testing on a minor NO NO NO NO NO NO
FIGURES
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